Brief: Enveric Biosciences Signs Non-Binding Term Sheets To Pursue The Exclusive Out-Licensing Of New Chemical Entities For Pharmaceutical And Non-Pharmaceutical Applications In Joint Disease
19/03/2024 11:14
March 19 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES SIGNS NON-BINDING TERM SHEETS TO
PURSUE THE
EXCLUSIVE OUT-LICENSING OF NEW CHEMICAL ENTITIES FOR
PHARMACEUTICAL AND NON-PHARMACEUTICAL APPLICATIONS IN JOINT
DISEASE
* ENVERIC COULD POTENTIALLY RECEIVE MILESTONE PAYMENTS THAT
TOTAL
UP TO APPROXIMATELY $82 MILLION
* ENVERIC - PHARMACEUTICAL APPLICATION TERM SHEET PROVIDES
THAT
ENVERIC COULD BE ELIGIBLE TO RECEIVE PAYMENTS IN TOTAL UP TO
APPROXIMATELY $61 MILLION
Source text for Eikon: ID:nBw26ZB2wa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003